Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  GenMark Diagnostics, Inc    GNMK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:31pm CET

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the GenMark investigation page on our website www.glancylaw.com/case/genmark-diagnostics-inc.

On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.

On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased GenMark securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENMARK DIAGNOSTICS, INC
11/14 GNMK Law Offices of Howard G. Smith Continues Investigation on Behalf of GenM..
11/10 GLANCY PRONGAY & MURRAY LLP : Continues Investigation on Behalf of GenMark Diagn..
11/08 GNMK Law Offices of Howard G. Smith Commences Investigation on Behalf of GenM..
11/08 GENMARK DIAGNOSTICS : to Present at the Canaccord Genuity Medical Technologies &..
11/07 GENMARK DIAGNOSTICS, INC : Bronstein, Gewirtz & Grossman, LLC Announces Investig..
11/03 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of GenMark Diagn..
11/03 Pomerantz Law Firm Investigates Claims On Behalf of Investors of GenMark Diag..
11/03 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of GenMark Diagnos..
11/03 Rosen Law Firm Announces Investigation of Securities Claims Against GenMark D..
11/02 GENMARK DIAGNOSTICS : reports 3Q loss
More news
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/07 YOUR DAILY PHARMA SCOOP : Anxious Time For Dynavax Longs, VBL Therapeutics Gets ..
11/06 YOUR DAILY PHARMA SCOOP : Progenics Looks Promising, Big Week For Dynavax, Keryx..
11/06 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
11/03 Midday Gainers / Losers
Financials ($)
Sales 2017 51,7 M
EBIT 2017 -57,7 M
Net income 2017 -60,6 M
Finance 2017 31,0 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 4,46x
EV / Sales 2018 3,84x
Capitalization 261 M
Chart GENMARK DIAGNOSTICS, INC
Duration : Period :
GenMark Diagnostics, Inc Technical Analysis Chart | GNMK | US3723091043 | 4-Traders
Technical analysis trends GENMARK DIAGNOSTICS, INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 11,0 $
Spread / Average Target 131%
EPS Revisions
Managers
NameTitle
Hany Massarany President, Chief Executive Officer & Director
James Charles Fox Chairman
Brian Mitchell Senior Vice President-Operations
Scott Mendel CFO & Principal Accounting Office
Jon Faiz Kayyem Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GENMARK DIAGNOSTICS, INC-61.03%261
THERMO FISHER SCIENTIFIC INC.34.78%75 857
DANAHER19.86%64 900
INTUITIVE SURGICAL85.67%43 977
BOSTON SCIENTIFIC CORPORATION30.65%38 807
ROYAL PHILIPS14.34%36 778